Article author:
New York — Pfizer Inc and BioNTech SE on Saturday, Omicron Coronavirus He said additional administration of an updated version of the COVID-19 vaccine specifically modified to combat the mutant resulted in a higher immune response to the mutant.
US Food and Drug Administration advisors will meet on Tuesday to discuss whether to renew the COVID-19 vaccine for the fall. According to experts, the updated shots are likely to be redesigned to fight the Omicron variant of the coronavirus.
Pfizer and BioNTech have shown that doses of 30 and 60 micrograms of shots targeting only the BA.1 omicron subvariant that was circulating last winter are neutralizing geometry for that subvariant. He said he induced a 13.5-fold and 19.6-fold increase in titer. Shot versions, including both the redesigned vaccine and the original vaccine, elicited 9.1-fold and 10.9-fold increases, they said.
The results are from a study of 1,234 people over the age of 56. The shot was well tolerated by the participants, the company said.
They found that in early laboratory studies, both Omicron modification candidates neutralize the recently circulating Omicron BA.4 and BA.5 subvariants. He said it suggests that. In the case of BA.1, the titer is about one-third. Both companies say they continue to collect data on how well boosters work against recently circulating strains.
Moderna Inc has also created a redesigned vaccine for the BA.1 Omicron subvariant. The company said the updated vaccine worked well against recent Omicron submutants and is in the process of seeking regulatory approval.
From the newsroom to the noon inbox, Toronto Sun's latest headlines, stories, opinions and photos. By clicking the
Thank you for registering.
A welcome email has been sent. If you don't see it, check your junk folder.
Your Midday Sun's next issue will arrive in your inbox shortly.
